Fresenius Medical Care AG (NYSE:FMS - Get Free Report) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 808,800 shares, a drop of 5.1% from the November 30th total of 852,500 shares. Based on an average daily trading volume, of 272,600 shares, the days-to-cover ratio is currently 3.0 days.
Analyst Ratings Changes
A number of analysts recently issued reports on FMS shares. Truist Financial boosted their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a report on Monday, October 7th. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a "buy" rating and a $25.60 target price on the stock. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They set a "strong-buy" rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $24.30.
Check Out Our Latest Research Report on Fresenius Medical Care
Fresenius Medical Care Stock Performance
FMS traded down $0.07 during trading on Tuesday, reaching $22.64. 83,757 shares of the company's stock were exchanged, compared to its average volume of 353,043. The company's fifty day simple moving average is $22.16 and its 200-day simple moving average is $20.61. The stock has a market capitalization of $13.29 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31.
Institutional Investors Weigh In On Fresenius Medical Care
Several hedge funds and other institutional investors have recently added to or reduced their stakes in FMS. Wulff Hansen & CO. grew its holdings in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock worth $6,556,000 after acquiring an additional 325,439 shares during the period. Moran Wealth Management LLC boosted its holdings in Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock worth $4,971,000 after buying an additional 74,621 shares in the last quarter. Quantinno Capital Management LP grew its position in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock valued at $2,345,000 after buying an additional 48,554 shares during the period. Crossmark Global Holdings Inc. increased its holdings in Fresenius Medical Care by 60.4% in the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after buying an additional 23,692 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Fresenius Medical Care during the 3rd quarter worth about $420,000. 8.37% of the stock is owned by institutional investors and hedge funds.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Read More
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
